Rates of and reasons for failure of commercial human immunodeficiency virus type 1 viral load assays in Brazil.
We examined failures of commercial human immunodeficiency virus type 1 (HIV-1) viral load assays of 1,195 plasma samples from Brazilian patients. Assay failure was assumed for samples in which the virus was undetectable by commercial assay but which tested positive by real-time reverse transcription-PCR of the HIV-1 long terminal repeat (LTR) region or if the viral load differed by >2 log10 from that determined by LTR assay. Failure rates for Bayer Versant bDNA 3.0, Roche Amplicor Monitor v1.5, and bioMerieux NucliSens QT were 0.68, 0.47, and 4.33%, respectively. NucliSens may be inadequate for use in Brazil.
Drexler
Jan Felix
JF
Bernhard Nocht Institute for Tropical Medicine, Clinical Virology Section, Bernhard Nocht Str. 74, 20359 Hamburg, Germany.
de Souza Luna
Luciano Kleber
LK
Pedroso
Celia
C
Pedral-Sampaio
Diana Brasil
DB
Queiroz
Artur T L
AT
Brites
Carlos
C
Netto
Eduardo M
EM
Drosten
Christian
C
D001483:Base Sequence; D021121:Branched DNA Signal Amplification Assay; D001938:Brazil; D003951:Diagnostic Errors; D015658:HIV Infections / Q000821:virology*; D016325:HIV Long Terminal Repeat / Q000235:genetics; D015497:HIV-1 / Q000145:classification / Q000235:genetics / Q000302:isolation & purification / Q000502:physiology*; D006801:Humans; D008969:Molecular Sequence Data; D021141:Nucleic Acid Amplification Techniques; D012367:RNA, Viral / Q000097:blood* / Q000235:genetics; D011933:Reagent Kits, Diagnostic; D020133:Reverse Transcriptase Polymerase Chain Reaction; D017422:Sequence Analysis, DNA; D019562:Viral Load / Q000592:standards
D012367:RNA, Viral; D011933:Reagent Kits, Diagnostic